BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma Selected for Presentation at 2024 ASCO Annual Meeting
BTAI Stock | USD 0.40 0.03 6.16% |
Under 66% of BioXcel Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding BioXcel Therapeutics suggests that many traders are alarmed. BioXcel Therapeutics' investing sentiment shows overall attitude of investors towards BioXcel Therapeutics.
BioXcel |
Poster presentation scheduled for June 1, 2024, 130-430 PM CT 230-530 PM ET Trial being led by Georgetown Universitys Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 --
Read at benzinga.com
BioXcel Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioXcel Therapeutics Fundamental Analysis
We analyze BioXcel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioXcel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioXcel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
BioXcel Therapeutics is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
BioXcel Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioXcel Therapeutics stock to make a market-neutral strategy. Peer analysis of BioXcel Therapeutics could also be used in its relative valuation, which is a method of valuing BioXcel Therapeutics by comparing valuation metrics with similar companies.
Peers
BioXcel Therapeutics Related Equities
ELEV | Elevation Oncology | 15.38 | ||||
INZY | Inozyme Pharma | 5.74 | ||||
AMLX | Amylyx Pharmaceuticals | 2.75 | ||||
MDGL | Madrigal Pharmaceuticals | 0.48 | ||||
EXEL | Exelixis | 0.06 | ||||
HEPA | Hepion Pharmaceuticals | 0.85 | ||||
TERN | Terns Pharmaceuticals | 0.90 | ||||
VKTX | Viking Therapeutics | 1.04 | ||||
DAWN | Day One | 2.66 | ||||
TGTX | TG Therapeutics | 3.03 | ||||
ABOS | Acumen Pharmaceuticals | 3.21 | ||||
MREO | Mereo BioPharma | 3.63 | ||||
XFOR | X4 Pharmaceuticals | 3.95 | ||||
APLS | Apellis Pharmaceuticals | 6.00 |
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |